Novartis Institutes for BioMedical Research

Novartis Institutes for BioMedical Research (NIBR), recently rebranded as Novartis Biomedical Research, serves as the global pharmaceutical discovery and early development engine for Novartis. Headquartered in Cambridge, Massachusetts, NIBR focuses on high-unmet-need areas including oncology, cardiovascular disease, immunology, and neuroscience. The organization is renowned for its science-first approach, prioritizing deep mechanistic understanding of disease to identify novel drug targets. NIBR utilizes a vast array of therapeutic modalities, ranging from traditional small molecules and biologics to cutting-edge cell and gene therapies and radioligand treatments. With major research hubs in the United States, Switzerland, and China, it fosters a highly collaborative environment involving thousands of scientists. NIBR's work is instrumental in populating the Novartis clinical pipeline, transitioning candidates from early discovery through proof-of-concept trials.